Congressional Subcommittee Probes FDA on its Plan to Regulate LDTs
September 10, 2014
 | Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Related Stories
- Legislators Question FDA, Stakeholders on How LDT Oversight Impacts Industry, Patients, Innovation September 10, 2014 / Pharmacogenomics Reporter
- Q&A: ACLA President Alan Mertz Discusses Citizen Petition Against FDA Regulation of LDTs June 12, 2013 / Pharmacogenomics Reporter
- Texas Congressman Drafts Bill to Keep Lab Test Oversight out of 'FDA's Lap,' Expand Authority of CMS October 19, 2011 / Pharmacogenomics Reporter
- Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business November 3, 2010 / Pharmacogenomics Reporter
- FDA Draft LDT Guidance Slated for Release in 60 Days; Industry Readying Recommendations, Objections August 6, 2014 / Pharmacogenomics Reporter
.png)
No hay comentarios:
Publicar un comentario